Accueil   Diary - News   All news VALBIOTIS selected to present 3 studies on TOTUM-63

VALBIOTIS selected to present 3 studies on TOTUM-63

VALBIOTIS selected to present 3 studies on TOTUM-63
by the European Association for the Study of Diabetes (EASD)

 

  • EASD, the leading European association in the field of diabetes, has selected the positive results of the international Phase II clinical study on TOTUM-63 in prediabetes to be presented next September in its 56th annual meeting. These results were selected by the American Diabetes Association last June 2020.
  • Additionally, two preclinical studies have also been selected, providing a better understanding of the multitargeted mode of action of TOTUM-63 and its efficacy in prevention and reversion of weight gain and its impact in the carbohydrate metabolism.
  • The value of VALBIOTIS’ scientific and clinical work keeps gaining momentum, with increased recognition from the international scientific community.

 

La Rochelle, September 21, 2020 (7:35 am CEST) VALBIOTIS (FR0013254851 - ALVAL, eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the selection of 3 studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD), which will be presented at the association’s annual meeting in September 2020.

 

Read the press release